Background: The sexual function of sexual minority women (women with female partners) who are breast cancer survivors is mostly unknown. Our objective is to identify explanatory factors of sexual function among sexual minority women with breast cancer and compare them with a control sample of sexual minority women without cancer.
introduction
Sexual dysfunction or difficulties remain a persistent concern of breast cancer survivors (BCS) [1] [2] [3] . Sexual dysfunction is common and distressing, affecting ∼50% of BCS [3] [4] [5] .
Depending on the dimension of sexual function (desire, arousal, orgasm, frequency of sexual activity) measured, the incidence of sexual dysfunction varies from 15% to a high of 64% [4, 5] . Broeckel et al. [6] demonstrated worse sexual functioning in long-term BCS compared with controls, including greater lack of sexual interest, inability to relax and enjoy sex, difficulty becoming aroused, and difficulty achieving orgasm. Study findings are inconsistent when sexual frequency is used as the measure of sexual functioning: Ganz et al. [4, 7] found no differences in the rate of sexual activity of BCS compared with healthy, age-matched postmenopausal women, while a more recent study demonstrated lower sexual frequency among BCS compared with controls [8] . The importance of comparing BCS to an age-matched control sample of healthy women is widely recognized, yet infrequently implemented [3, 4, 6, 8] .
Greater consensus exists with respect to the etiology of sexual problems in BCS, believed to be caused by an interaction between physiological, psychological, and interpersonal factors [3, 7] . Physiological predictors include severity of the disease, extent of cancer treatment, and comorbidities [9] . A more positive body image is linked to better sexual functioning after breast cancer [7] . Interpersonal factors include partner and relationship dynamics [3, 4, 7] .
To date, research on sexual problems in BCS has neglected attention to sexual orientation [10] . Most studies focus on heterosexual or presumed heterosexual women, without regard for sexual minority women (SMW), whom we define as lesbian or bisexual-identified women and women who report a preference for a female partner. Little is known about the specific predictors of sexual function in this population and about differences in the predictors of sexual problems of sexual minority breast cancer survivors (SMBCS) compared with controls. Two studies found no significant differences in sexual frequency and sexual satisfaction of lesbian BCS compared with heterosexual BCS [11, 12] . Results of these studies were discordant with respect to the role of relationship dynamics as an explanatory factor of sexual function. Fobair et al. [12] found that lesbians were significantly more likely than heterosexual women to report that their partner made them feel loved and cared for, were willing to listen, and could be counted on to help with daily tasks. In contradistinction, Arena et al. [11] found no differences between lesbians and heterosexual women with respect to overall relationship satisfaction or in reports of how much affection their partners demonstrated, how bothered their partners were by their surgical scar, the extent to which their partners reacted to breast cancer as a threat to their life, or whether there was increased fighting or friction between members of the couple [11] .
The sexual function of SMW BCS and its causal factors is in need of research attention, as documented by a recent review of sexual issues among SMW [10] . Using the conceptual framework for sexual functioning of BCS created by Ganz et al. [7] , we conducted a case-control study of SMBCS and compared them to an age-and partner status-matched control group of SMW without cancer. Our aim was to identify the explanatory predictors of sexual function in SMBCS and compare them to SMW without cancer. Given previous findings, that sexual functioning of sexual minority and heterosexual BCS is similar [11, 12] , we hypothesized that predictors of sexual function in SMBCS would not differ significantly from the predictors of sexual function in SMW without cancer. methods data Our study data were obtained by convenience recruitment. Advertisements, fliers, and promotional materials were distributed to a variety of organizations, print media, Internet websites, and at events [i.e. lesbian cancer projects; breast cancer support groups; lesbian, gay, bisexual, and transgender (LGBT) agencies; and cancer or LGBT-focused events, including LGBT pride]. As an incentive, we offered $20 for participation. Interested women who contacted us were screened by telephone; those who were eligible were invited to participate in an anonymous mail survey.
Eligibility for this study depended on sexual minority status, which we defined as self-identification as lesbian or bisexual, or reporting a preference for a female partner. Women who were currently in a relationship with a male partner were excluded. No restrictions were imposed with respect to partnership status or sexual frequency over a predetermined time period.
To ensure that we capture SMBCS (cases) when they recovered from the immediate impact of the diagnosis and the invasive breast cancer treatments, study eligibility was defined as follows: (i) a diagnosis of breast cancer, staged 0, I, II, or III; (ii) at the time of the survey, the breast cancer diagnosis was 1 to 10 years ago; and (iii) no current active cancer-related treatments, defined as surgery, chemotherapy, or radiation. We allowed the participation of women with breast cancer recurrence and women currently receiving antiestrogen therapies, including tamoxifen and aromatase inhibitors. We chose these selection criteria to assess sexual well-being of disease-free long-term survivors, after a minimum of 1 year after initial diagnosis had passed, when survivors have overcome the immediate effects of breast cancer treatments [13] . Women with metastatic disease were excluded from this study because metastatic disease often requires ongoing cancer treatments to address metastases or associated symptoms, including pain, which has been shown to result in poor sexual function [14] .
Control participants were eligible if they (i) Had no history of cancer; (ii) had neither undergone prophylactic mastectomy nor oophorectomy; and (iii) were not currently using systemic estrogen or estrogen plus progesterone replacement hormones. Each control was age-matched to a case, defined as being within 3 years of a case in age. We further matched controls by case partner status, defined as being partnered or unpartnered because the availability of a partner has been repeatedly shown to be positively linked to sexual frequency and functioning [15] [16] [17] [18] .
measures
Sexual function was the outcome of interest, which was assessed using a modified version of the Female Sexual Function Index (FSFI) [19] . We adapted the FSFI instructions to SMW by substituting 'Sexual intercourse is defined as penile penetration (entry) of the vagina' with 'Vaginal penetration is defined as penetration (entry) of the vagina with any object (fingers, sex toys)'. We reduced the FSFI's bias toward dysfunction for participants who were sexually inactive by revising the scoring of the FSFI to treat values of zero as missing data and required that a minimum of 9 of the 19 possible items of the FSFI had responses other than zero [20] . Scores were rescaled to the full FSFI range of 0-36.
Consistent with the aforementioned conceptual framework [7] , we collected information about the five potential predictors of sexual function: (i) demographic and personal characteristics, (ii) breast cancer and related medical variables, (iii) body image, (iv) partner relationship, and (v) health-related quality of life. (i) Demographic information included age in years, race/ethnicity categorized into white and nonwhite, and socioeconomic status measures. These included respondents' education, individual income, categorized into < $30 000, $30 000-$69 999, and ≥$70 000 or more; and health insurance status, categorized as no health coverage, public, or private coverage. Employment status distinguished between respondents who were unemployed and employed, which included full or part-time employment. (ii) Medical variables consisted of body mass index, categorized into normal, overweight, and obese; menstrual status to differentiate premenopausal from menopausal women; menopause original articles Annals of Oncology symptoms, assessed through the Menopause Rating Scale [21] , and comorbidity, assessed through a measure of cardiopulmonary comorbidity, which has previously been shown to better predict the physical function of breast cancer patients than the Charlson Index [22] . For respondents with breast cancer, we derived years since diagnosis, stage of cancer, recurrence, and cancer-related treatments. (iii) Body image was measured using the body esteem scale [23] , which assessed sexual attractiveness, weight concern, and physical condition, with higher scores indicating a more positive body esteem. (iv) Partner-related variables distinguished partnered women from unpartnered women and relationship variables for partnered women, which included length of relationship, partner's sexual problems, and the quality of the relationship as measured by two subscales of the dyadic adjustment scale [24] , the dyadic cohesion and the dyadic satisfaction scale. (v) Quality of life was assessed using the SF-12 [25] from which we derived the Mental Component Summary and the Physical Component Summary scales, each of which is standardized to range from 0 to 100, with higher scores indicating a more favorable status. In addition, we considered depression and anxiety, assessed through the Hospital and Anxiety Depression Scale [26] .
analysis All analyses were carried out using SAS version 9.1 (SAS Inc., Cary, NC) and were conducted at significance level 0.05. We used t-tests or linear regression for between-group comparisons on continuous outcomes and chi-squared tests or logistic regression for comparisons on categorical variables. We used stepwise selection to identify which of the significant predictors of sexual function should be entered into the model and to estimate model fit. We examined the selected predictors for collinearity and then used generalized estimating equations (GEE) implemented in SAS Proc Genmod (SAS Inc., Cary, NC) to account for intraclass correlation induced by matching cases and controls on age and partner status.
results
As shown in supplemental Table S1 (available at Annals of Oncology online), both case and control samples were reasonably well matched on age and partner status, although control participants were slightly younger compared with cases. Less than one-third of participants were unpartnered in both groups. Cases and controls were similar with respect to race, education, income, and employment. The majority of participants were white and highly educated, with about half having completed graduate school. Approximately three quarters of participants in each sample made < $70 000 and ∼80% were employed. Significantly more cases had health insurance coverage compared with controls.
Participants with breast cancer were on average 4.5 years post-diagnosis and < 4% reported a recurrence. Only 41% were treated with breast-conserving lumpectomy. Among the participants treated with mastectomy, about one-third chose breast reconstruction. About 60% of participants received chemotherapy or radiation. About one-third never received antiestrogen therapy, while 46% continued to receive this treatment at the time of study. Table 1 compares case and control samples on key predictor variables. Cases and controls differed on body esteem, in which controls rated their sexual attractiveness significantly higher. Body mass index (BMI) was similar in both groups; less than half reported normal weight. The two samples did not differ significantly on cardiopulmonary comorbidities, with both reporting fewer than two comorbidities on average. Significantly more cases were menopausal and reported more severe menopause-related symptoms. When considering the subscales, cases reported significantly more urogenital and somatic symptoms. Cases and controls were similar with respect to physical and mental quality of life, anxiety, and depression. Among partnered women, significantly more controls reported that their partner had a sexual problem, while relationship duration was significantly longer among cases. Partner relationships of cases and controls were similar with respect to cohesion and satisfaction. Supplemental Table S2 (available at Annals of Oncology online) shows bivariate relationships of the various categorical predictors and sexual function. The last column indicates the significance of each predictor while controlling for case status. Partner status, race, education, income, employment, health insurance, BMI, and partner's sexual problems were not significantly associated with sexual function. Pre-or perimenopausal women had significantly better sexual function compared with menopausal women. There were no significant associations between any of the cancer-related variables and sexual function. Table 2 shows the bivariate associations of continuous predictor variables using models that include the continuous variable while controlling for case status. Age, physical well-being, comorbidity, and time since diagnosis were unrelated to sexual function. We found significant positive associations between each dimension of body image and sexual function. Menopausal symptoms and each subscale were significantly inversely associated with FSFI scores. Better mental well-being was significantly associated with improved sexual function, whereas anxiety and depression impacted sexual function negatively. Among partnered women, longer relationship duration had an adverse effect on sexual function, whereas greater dyadic cohesion had a positive impact and dyadic satisfaction was not significantly associated. For both tables (Table 2 and supplemental Table S2 , available at Annals of Oncology online), only some of the partner-related variables differed significantly by case status. For each variable, i.e. partner's sexual problems, dyadic cohesion, and satisfaction, cases had worse sexual function. Table 3 shows results of modeling sexual function. We initially considered all variables that had significant bivariate associations with FSFI, removed variables that were collinear, while retaining those that remained significant when several variables were considered simultaneously. When controlling for case status, sexual attractiveness and urogenital symptoms explained 44% of the variability in sexual function. As partnerrelated variables only apply to women in relationships, we modeled partnered women's sexual function separately. For partnered women, we found that 45% of the variability in sexual function was explained by sexual attractiveness, urogenital symptoms, menopausal status, and dyadic cohesion, regardless of case status. In this model, menopausal women had worse sexual function and dyadic cohesion was only original articles Annals of Oncology marginally significant (P = 0.0663), likely limited by our sample size of partnered women.
discussion
Our hypothesis that predictors of sexual function in SMBCS do not differ significantly from predictors of sexual function in SMW without cancer was mostly confirmed. We did find minor differences by case status, when the sample was restricted to partnered women. The conceptual framework previously applied to heterosexual women with breast cancer [7] appears to be well suited for SMBCS and SMW controls. This conceptual model was able to explain 44% of the variability in sexual function, with higher perceived sexual attractiveness positively, and urogenital symptoms negatively, associated with sexual function. The variability of sexual function of women in relationships was best explained by sexual attractiveness, urogenital symptoms, menopausal status, and dyadic cohesion. In our study, none of the breast cancer-related treatments had a significant impact on sexual function among SMBCS ( Table 3 ). The literature on BCS is inconsistent in this respect: some studies find no link, while others point to treatments causing dysfunction [3, [27] [28] [29] [30] [31] . In our study of SMW, neither having a partner with a sexual problem nor a woman's satisfaction with her relationship had significant impact on sexual function, in contradistinction to findings among heterosexual BCS [7] .
One of the most valuable contributions of this study is the ability to compare cases and controls. Our findings indicate that long-term SMBCS do not differ from age-matched controls with respect to comorbidity, anxiety, depression, mental, and physical well-being. This is inconsistent with findings from studies of the general population, which link a history of breast cancer to worse long-term mental and physical well-being, at least in a subset of patients [32] [33] [34] [35] . Studies of heterosexual women concluded similar sexual function among cases and controls [4, 7] . In our sample of SMW, a history of breast cancer had no apparent detrimental effect on women's relationships, which is consistent with a case and control study of heterosexual women that found no differences in marital functioning between affected women and controls [6] .
In this study, we were able to identify relevant predictors of sexual function in SMW. Perceived greater sexual attractiveness and worse urogenital symptoms predict sexual function. For partnered women, greater dyadic cohesion and postmenopausal status had an additional impact. This is important information for clinicians treating SMW and for the development of interventions to improve sexual function in this population. A number of psychosocial interventionsparticularly ones that are group based-exist to address body image and relationship concerns [34, 36, 37] . Urogenital symptoms can be alleviated by providing education regarding the need for greater intensity and duration of genital stimulation after menopause, such as can be achieved by the use of mechanical devices [38] , and advocating for the use of sexual lubricants and vaginal moisturizers [39] , low-dose vaginal estrogen [40, 41] , and pelvic floor therapies [42, 43] .
Additional research and efforts are needed to adapt these approaches to accommodate the specific preferences and sexual practices of SMW.
There are several limitations to our study. We used convenience sampling because without surveillance data, population-based samples of SMW with and without breast cancer cannot be conducted [44] . Similar to other studies of sexual function in BCS, we lack data on sexual function before diagnosis. While we report associations between the FSFI and study variables, we cannot draw firm conclusions about the exact etiology of sexual dysfunction. Finally, while we chose the FSFI because it had been previously used to measure sexual function in SMW [45] and made modifications to enhance its cultural relevance [20] , the reliability of this instrument has not been tested in this population [46] .
To our knowledge, this is the first study comparing SMBCS to age-and partner status-matched controls. Our results underscore the importance of asking all BCS, including SMBCS, about their sexual function, and of including specific assessment of body esteem, relationship satisfaction, and menopausal symptoms. Additional research is needed to confirm our findings, expand our understanding of sexual function in SMBCS, and develop culturally relevant interventions to enhance sexual satisfaction in this population.
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